Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

BIII 890 CL

Known as: 1,2,3,4,5,6-hexahydro-6,11,11-trimethyl-3-(2-(phenylmethoxy)propyl)-2,6-methano-3-benzazocin-10-ol, BIII-890-CL 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Benzomorphans

Narrower (1)

crobenetine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2002
Review
2002
BIII-890-CL. Boehringer Ingelheim.
  • Jay Meythaler
  • Current opinion in investigational drugs
  • 2002
  • Corpus ID: 2158593
BIII-890-CL is a non-orally active sodium channel blocker under development by Boehringer Ingelheim Corp for the potential… 
2000
2000
Potent blockade of sodium channels and protection of brain tissue from ischemia by BIII 890 CL.
We have synthesized a new benzomorphan derivative, 2R-[2alpha,3(S*), 6alpha]-1,2,3,4,5,6-hexahydro-6,11, 11-trimethyl-3-[2… 
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE